



# BRAZIL

•






# **Impact of Antiretroviral Therapy (1995 - 2000)**

- ✓ **Reduced Mortality ➤ 40-70%**
- ✓ **Reduced Morbidity ➤ 60-80%**
- ✓ **Reduced Hospitalization**
  - **234,000 avoided**
- ✓ **Cost Savings ➤ U\$ 711 million**

# Brazil: ARV Price Reduction According to the Source of Production



0.08 0.08 0.08 0.56 0.17 0.23 0.45 0.14 0.05

## **Cost Impact of the ARV Therapy generated by drugs between 1997-2000**

- Net savings of US\$ 200/250 million, between 1997 and 2000, considering as a basis 1997 prices and increase in the number of patients from 27.000 to 92.000;
- Only in the year 2000 savings of US\$ 80 million (approximately 30% of the total cost) with the beginning of the National Production of Nevirapine and Indinavir.
- Savings of US\$ 40 million in 2001 as consequence of the Agreement with Merck

# **Brazilian MoH & Merck Agreement on ARV Price Reduction (March, 2001)**

- 64,8 % Price Reduction on Indinavir  
U\$ 1.33/capsule  $\Rightarrow$  U\$ 0.47/capsule
- 59,0 % Price Reduction on Efavirenz  
U\$ 2.05/capsule  $\Rightarrow$  U\$ 0.84/capsule

# Global Agreement for an Equitable Access to AIDS Treatment

- Protection of local production of AIDS drugs legislation;
- International funding for developing countries acquisition of AIDS drugs
- Differential price policy of AIDS drugs for developing countries (equitable basis);
- Incentives and subsidies to the research and development of new drugs for public and private institutions.
- International technical support to adequate use of antiretroviral drugs.